Reporting quality of economic evaluations of the negotiated Traditional Chinese Medicines in national reimbursement drug list of China: A systematic review

被引:1
作者
Yan, Juntao [1 ,2 ]
Bao, Shiyi [1 ,2 ]
Liu, Liu [1 ,2 ]
Zhang, Yu-Qing [3 ,4 ,5 ,6 ]
Ming, Jian [1 ,2 ,7 ]
Wei, Yan [1 ,2 ]
Chen, Yingyao [1 ,2 ]
机构
[1] Fudan Univ, Sch Publ Hlth, 138Yi Xue Yuan Rd, Shanghai 200032, Peoples R China
[2] Fudan Univ, Natl Hlth Commiss Key Lab Hlth Technol Assessment, Shanghai, Peoples R China
[3] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[4] Guanganmen Hosp, China Acad Chinese Med Sci, CEBIM Ctr Evidence Based Integrat Med Clar Collabo, Beijing, Peoples R China
[5] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China
[6] Univ Nottingham Ningbo, Nottingham Ningbo GRADE Ctr, Ningbo, Peoples R China
[7] IQVIA Solut Enterprise Management Consulting Shang, Shanghai, Peoples R China
关键词
Economic evaluation; Traditional Chinese medicine; Appraisal of reporting qualit; CHEERS;
D O I
10.1016/j.imr.2022.100915
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Traditional Medicine (TM) has a wide uptake in most countries. In China, Traditional Chinese Medicine (TCM) is a common kind of primary health because of its beneficial effects. This review aimed to appraise the publication reporting quality of economic evaluations for selective TCM in the National Reimbursement Drug List (NRDL), Version 2020, based on the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Methods: Electronic databases were searched for economic evaluation that supported the TCM negotia-tions in NRDL (2020 version) published from 2001 to 2021, including PubMed, Web of Science, Embase, CNKI, WanFang, and SinoMed. The CHEERS statement was used to appraise the reporting quality of in-cluded TCM economic evaluations.Results: A total of 360 articles were retrieved, but only 38 economic evaluations met the inclusion crite-ria. None of the articles reported all items in the CHEERS checklist. The mean score of included articles is low at 10.93 +/- 2.62, with an average scoring rate of 51.31 +/- 10.53%. The least reported items included: "Characterizing heterogeneity," "Conflicts of interest", "Discount rate," and "Study perspective," with a re-porting rate of 0.00%, 5.26%, 7.89%, and 15.79%, respectively. Conclusion: An upward trend occurred in the quantity and quality of the economic evaluation publica-tions of TCM in China. TCM economic evaluations are still at an early stage, with an urgent need for improving reporting quality. It may result from research experiences or different ideas between TCM and Western Medicine. Adhering to reporting guidelines like CHEERS and educating economic evaluation in-vestigators can improve TCM economic evaluations' reporting quality.(c) 2023 Korea Institute of Oriental Medicine. Published by Elsevier B.V.This is an open access article under the CC BY-NC-ND license( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页数:10
相关论文
共 69 条
[1]  
[Anonymous], WHO traditional medicine strategy: 2014-2023
[2]  
Bin H., 2018, CHINA MOD MED, V25, P141
[3]  
Bing T, 2013, EVAL ANAL DRUG USE H, V13, P494
[4]   Challenges and opportunities of integrating traditional Chinese medicine into mainstream medicine: A review of the current situation [J].
Chan, Kelvin ;
Hu, Xiao-Yang ;
Razmovski-Naumovski, Valentina ;
Robinson, Nicola .
EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2015, 7 (01) :67-75
[5]   Health technology assessment and economic evaluation: Is it applicable for the traditional medicine? [J].
Chen, Yingyao .
INTEGRATIVE MEDICINE RESEARCH, 2022, 11 (01)
[6]   Development of health technology assessment in China: New challenges [J].
Chen, Yingyao ;
He, Yao ;
Chi, Xunyouzhi ;
Wei, Yan ;
Shi, Lizheng .
BIOSCIENCE TRENDS, 2018, 12 (02) :102-108
[7]  
Chuanping J, 2018, DRUG EVAL RES, V41, P1191
[8]   METHODOLOGICAL AND CONDUCT PRINCIPLES FOR PHARMACOECONOMIC RESEARCH [J].
CLEMENS, K ;
TOWNSEND, R ;
LUSCOMBE, F ;
MAUSKOPF, J ;
OSTERHAUS, J ;
BOBULA, J .
PHARMACOECONOMICS, 1995, 8 (02) :169-174
[9]  
Clinical research collaborative group of Xinmailong InjectionClinical research collaborative group of Xinmailong Injection, 2020, CHIN J HEART FAIL CA, V4, P191
[10]   Adaption and Application of the Four Phase Trials to Traditional Chinese Medicines [J].
Di, M. Y. ;
Tang, J. L. .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013